Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
Precigen (NASDAQ: PGEN) announced its participation in two upcoming virtual fireside chats to discuss their recently FDA-approved therapy for adult recurrent respiratory papillomatosis. The first event, hosted by Jennifer Kim of Cantor, is scheduled for August 27, 2025, while the second chat, moderated by Dr. Swayampakula Ramakanth of H.C. Wainwright, will take place on September 2, 2025.
Both events will feature presentations from Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer. Investors can access the live webcasts through Precigen's investor relations website.
Precigen (NASDAQ: PGEN) ha annunciato la partecipazione a due prossimi incontri virtuali per discutere della terapia recentemente approvata dalla FDA per la papillomatosi respiratoria ricorrente negli adulti. Il primo evento, condotto da Jennifer Kim di Cantor, è in programma per il 27 agosto 2025, mentre il secondo, moderato dal Dr. Swayampakula Ramakanth di H.C. Wainwright, si terrà il 2 settembre 2025.
In entrambi gli appuntamenti interverranno Helen Sabzevari, PhD, President and CEO, e Phil Tennant, Chief Commercial Officer. Gli investitori potranno seguire le webcast in diretta dal sito web per gli investitori di Precigen.
Precigen (NASDAQ: PGEN) anunció su participación en dos próximos coloquios virtuales para hablar sobre su terapia recientemente aprobada por la FDA para la papilomatosis respiratoria recurrente en adultos. El primer evento, presentado por Jennifer Kim de Cantor, está programado para el 27 de agosto de 2025, y el segundo, moderado por el Dr. Swayampakula Ramakanth de H.C. Wainwright, tendrá lugar el 2 de septiembre de 2025.
En ambos eventos participarán Helen Sabzevari, PhD, President and CEO, y Phil Tennant, Chief Commercial Officer. Los inversores podrán acceder a las retransmisiones en directo a través del sitio web de relaciones con inversores de Precigen.
Precigen (NASDAQ: PGEN)은 성인의 재발성 호흡기 유두종증 치료제로 최근 FDA 승인을 받은 신약을 논의하기 위해 예정된 두 건의 가상 파이어사이드 챗에 참여한다고 발표했습니다. 첫 번째 행사는 Cantor의 Jennifer Kim이 진행하며 2025년 8월 27일에, 두 번째 행사는 H.C. Wainwright의 Dr. Swayampakula Ramakanth가 사회를 맡아 2025년 9월 2일에 열립니다.
두 행사에는 Helen Sabzevari 박사, President and CEO와 Phil Tennant, Chief Commercial Officer가 발표자로 참여합니다. 투자자들은 Precigen의 투자자 관계 웹사이트를 통해 생중계 웹캐스트에 접속할 수 있습니다.
Precigen (NASDAQ: PGEN) a annoncé sa participation à deux entretiens virtuels à venir pour évoquer sa thérapie récemment approuvée par la FDA contre la papillomatose respiratoire récurrente chez l'adulte. Le premier événement, animé par Jennifer Kim de Cantor, est prévu le 27 août 2025, et le second, modéré par le Dr Swayampakula Ramakanth de H.C. Wainwright, se tiendra le 2 septembre 2025.
Les deux sessions incluront des présentations de Helen Sabzevari, PhD, President and CEO, et de Phil Tennant, Chief Commercial Officer. Les investisseurs pourront accéder aux webcasts en direct via le site relations investisseurs de Precigen.
Precigen (NASDAQ: PGEN) gab bekannt, an zwei bevorstehenden virtuellen Fireside-Chats teilzunehmen, um über die kürzlich von der FDA zugelassene Therapie bei rezidivierender respiratorischer Papillomatose bei Erwachsenen zu sprechen. Die erste Veranstaltung, moderiert von Jennifer Kim von Cantor, ist für den 27. August 2025 geplant, die zweite, geleitet von Dr. Swayampakula Ramakanth von H.C. Wainwright, findet am 2. September 2025 statt.
Bei beiden Terminen werden Helen Sabzevari, PhD, President and CEO, und Phil Tennant, Chief Commercial Officer präsentieren. Investoren können die Live-Webcasts über Precigens Investor-Relations-Website verfolgen.
- None.
- None.
Cantor Virtual Fireside Chat
August 27, 2025, 11 AM – 12 PM ET
Host: Jennifer Kim, Biotech Analyst, Cantor
Participants: Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen
H.C. Wainwright Virtual Fireside Chat
September 2, 2025, 11 AM – 12 PM ET
Moderator: Swayampakula Ramakanth, PhD, Managing Director, Equity Research, H.C. Wainwright
Participants: Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen
Participants may access the live webcasts of the virtual events through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with Precision®
Precigen (Nasdaq: PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.
Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
investors@precigen.com
Media Contact:
Donelle M. Gregory
press@precigen.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-participate-in-upcoming-virtual-fireside-chats-hosted-by-cantor-and-hc-wainwright-302537276.html
SOURCE Precigen, Inc.
FAQ
When are Precigen's (PGEN) upcoming virtual fireside chats scheduled for?
Who will be presenting at Precigen's (PGEN) virtual fireside chats?
What will be discussed at Precigen's (PGEN) virtual fireside chats?
How can investors access Precigen's (PGEN) virtual fireside chats?
